Connect with us

Biotech

Norbel Inversiones Divests 3% of Rovi’s Share Capital

Norbel Inversions, the investment vehicle of the López-Belmonte family, owners of the pharmaceutical company, wants to sell 1.6 million shares. The transaction will be carried out through a procedure known as “accelerated bookbuilding” and is expected to last no more than one day, according to the Spanish pharmaceutical company

Published

on

Norbel Inversiones reduces its stake in Laboratorios Rovi. Bestinver and Jefferies International are carrying out on behalf of this investment vehicle of the López-Belmonte family, owners of the pharmaceutical company, a placement of up to 1.6 million shares representing 3% of the capital stock. The amount of the placement will total more than $103.7 million (€87 million), with a unit sale price of $62 (€52) per share.

The transaction will be carried out through a procedure known as “accelerated bookbuilding” and is expected to last no more than one day, according to the Spanish pharmaceutical company in a statement sent to the Spanish Securities and Exchange Commission (Comisión Nacional del Mercado de Valores, Cnmv).

The will of the seller, which is and will continue to be the majority shareholder of Rovi, is to gradually increase the liquidity of the stock, “having committed the seller with the placement entities to maintain a lock-up of its remaining participation during a period of 90 days,” Rovi informed in the note.

Find out more details about Norvel Inversions and Rovi and read the latest business headlines with our companion app Born2Invest.

Norbel Inversiones seeks to increase the liquidity of the stock with this operation

The placement process will begin immediately and during this period the entities in charge of carrying out this operation will develop diffusion and promotion activities with the aim of “obtaining indications of interest or proposals of acquisition of the shares by potential investors,” the pharmaceutical company pointed out.

The Spanish drugmaker posted a net profit of $73 million (€61.1 million) in 2020, 55% higher than in 2019 when it earned $47 million (€39.3 million). Rovi’s operating income increased by 10% in 2020 over the previous year to $500 million (€420 million). These results are due, according to the group, to the strength of the third-party manufacturing business, which grew by 39% in sales following the agreement for Moderna’s COVID-19 vaccine, as well as the specialty pharmaceuticals business, whose turnover increased by 4%.

SEE ALSO  Capstone optimistic about what’s ahead with latest favorable findings

Within the sales achieved in 2020 by Rovi, those of the heparins division (low molecular weight heparins and other heparins) increased by 14% to $250 million (€209.3 million), representing 50% of operating revenues in 2020, compared with 48% in 2019. Sales of Neparvis, which Rovi began marketing in December 2016, increased 34% to $35.5 million (€29.6 million) in 2020.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Leah Marie Angelou is an LGBTI activist and equality advocate. She has been a writer for several feminism-focused groups for nearly a decade. Her pieces are often focused on career development and the workplace. She also regularly covers personal and micro-finance, business management and entrepreneurship. Recently she has also focused on covering the promising CBD and hemp industry.